Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 1228; p. 123801
• Main Authors: Herrera-Pérez, Ivette Guadalupe, Rodríguez-Báez, Ana Socorro, Ortiz-Álvarez, Arturo, Velarde-Salcedo, Rodrigo, Arriaga-García, Francisco Javier, Rodríguez-Pinal, Cristian Jazmín, Romano-Moreno, Silvia, Milán-Segovia, Rosa del Carmen, Medellín-Garibay, Susanna Edith
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.08.2023
• Subjects: Dried blood spots; First line anti-tuberculosis drugs; Therapeutic drug monitoring; Tuberculosis; UPLC-MS/MS; LLOQ; INH; MRM; Cp; Therapeutic drug monitoring; CCs; DBS; ME; ESI; EMB; TDM; QCs; LOD; Cmax; Dried blood spots; First line anti-tuberculosis drugs; DOTS; TB; Tuberculosis; CV; RMP; UPLS-MS/MS; PZA; Tmax; Hct; UPLC-MS/MS
• ISSN: 1570-0232; 1873-376X
• DOI: 10.1016/j.jchromb.2023.123801

•UPLC-MS/MS conditions were standardized to quantify first-line antiTB drugs.•Bioanalytical methods based on microsampling strategies were validated.•AntiTB drugs were quantified in plasma and capillary blood from TB patients.•Clinical applicability of bioanalytical methods was demonstrated for TDM purposes. Tuberculosis (TB) is a high-burden infectious disease with high prevalence and mortality rates. The first-line anti-TB drugs include isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB). At present, the standard method of blood sampling for therapeutic drug monitoring (TDM) analysis is venipuncture. Dried blood spots (DBS) are a minimally invasive method for collecting small quantities of whole blood from fingertips. The aim of the current study was to develop an ultrahigh-performance liquid chromatography technique coupled to tandem mass spectrometry (UPLC-MS/MS) for simultaneous quantification of the first-line anti-TB drugs in human plasma and DBS as a sampling alternative. The separation and detection conditions were optimized to quantify INH, RMP, PZA, and EMB in both matrices in an ACQUITY UPLC H Class system coupled to a XEVO TQD detector. Chromatographic separation was performed through an Acquity HSS T3 column (2.1 × 100 mm, 1.8 μm) with 0.1% formic acid in water and acetonitrile as the mobile phase. The total run time was 7 min for both methods, with retention time in plasma of 0.85, 1.22, 3.16, and 4.04 min and 0.74, 0.87, 0.97, and 4.16 min for EMB, INH, PZA, and RMP in DBS, respectively. The bioanalytical methods developed were proved selective, linear, precise, and accurate (inter- and intra-assay); the matrix effect was demonstrated to be within the established limits. Short- and long-term stability, freeze–thaw cycles for plasma, and short-term stability for DBS were established. A total of 15 patients with 46 ± 17 (mean ± SD) years old were included, and anti-TB drug concentrations were quantified on plasma and DBS as proof of concept. Based on RMP and INH plasma concentrations (Cp), and Bayesian estimation of individual pharmacokinetic parameters, a dose adjustment was necessary for 93% of patients. The slopes of the correlation lines between plasma and DBS concentrations of RMP, EMB, INH, and PZA were 0.5321, 0.8125, 0.5680, and 0.6791, respectively. Finally, significant correlations (p < 0.05) were observed between DBS and plasma concentrations for RMP (r2 = 0.6961), EMB (r2 = 0.4369), INH (r2 = 0.8675) and PZA (r2 = 0.7363). A simple, fast, and reliable UPLC-MS/MS method was developed to quantify first-line anti-TB drugs in plasma and DBS, which provides an easy sampling and storage to be applied as a new strategy for TDM in patients with TB.